Evaluation of palliative therapy, alone or in combination with toceranib phosphate, in dogs diagnosed with metastatic or recurrent beta-cell neoplasia

Alonso-Miguel, Daniel; José, Paula García San; Sanz, Sandra; Moral, Irene; Alenza, María Dolores Pérez

doi:10.1080/00480169.2021.1905569

Cited by 8 publications

(9 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One retrospective study and one case report for the use of toceranib in dogs with insulinoma were identified 49,50 . In the retrospective study, 12 dogs with metastatic or recurrent insulinoma were included; seven dogs (control group) were treated with palliative care only, while five dogs were treated with palliative care and toceranib (treatment group) 50 . The dogs in the treatment group had a statistically significant longer overall survival time compared to the control group (399 vs. 67 days) 50 .…”

Section: Resultsmentioning

confidence: 99%

“…In the retrospective study, 12 dogs with metastatic or recurrent insulinoma were included; seven dogs (control group) were treated with palliative care only, while five dogs were treated with palliative care and toceranib (treatment group) 50 . The dogs in the treatment group had a statistically significant longer overall survival time compared to the control group (399 vs. 67 days) 50 . There was limited information regarding the reason for allocation of dogs to each group, which could potentially bias the results.…”

Section: Resultsmentioning

confidence: 99%

“…Another promising area is the treatment of neuroendocrine tumours. Sunitinib has been licensed for the treatment of neuroendocrine pancreatic cancer in people 85 while promising findings have been described in some case reports and retrospective studies in dogs with thyroid carcinoma, insulinoma, phaechromocytoma and heart base tumours treated with toceranib 46,47,50,51,53 . In addition, dogs with ASAC, that is considered a neuroendocrine tumour, showed benefit when treated with toceranib 28–32 .…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

The role of toceranib phosphate in dogs with non‐mast cell neoplasia: A systematic review

Frezoulis¹,

Harper²

2022

Vet Comparative Oncology

View full text Add to dashboard Cite

The use of tyrosine kinase inhibitors (TKI) has gained significant importance in veterinary cancer patients over the last decade. Toceranib phosphate has been licensed for the treatment of dogs with mast cell tumours. Its molecular similarity to sunitinib, a TKI used in human medicine, has led many veterinary oncologists to use this agent for multiple neoplastic diseases. The aim of the current study was to perform a systematic review of the evidence for the use of toceranib in dogs with non‐mast cell neoplasia. Two electronic databases were searched. Publications were included if toceranib was used as a treatment option in canine patients. Studies and case reports were excluded if toceranib was used as part of a multi‐modal treatment plan and response or outcome data related to toceranib therapy were not described. A total of 28 studies were included from 122 references. The most common types of neoplasias identified were neuroendocrine tumours, anal gland sac adenocarcinoma, and osteosarcoma. Multiple other neoplasias had one or two studies identified to describe the use of toceranib. Results of the study support that toceranib phosphate may have efficacy against certain types of neoplasia under certain conditions, such as neuroendocrine tumours, gastrointestinal stromal tumours and anal sac adenocarcinomas, while it is probably not effective for the management of metastatic osteosarcoma based on the findings of the review.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The role of toceranib phosphate in dogs with non‐mast cell neoplasia: A systematic review

Frezoulis¹,

Harper²

2022

Vet Comparative Oncology

View full text Add to dashboard Cite

show abstract

“…Toceranib phosphate (TOC) is a multi-targeted receptor tyrosine kinase inhibitor (TKI) approved for use in dogs. TOC was originally indicated for the treatment of recurrent Patnaik grades 2 and 3 cutaneous mast cell tumors (MCTs) [ 11 ] but has also been shown to be effective against various solid tumors, including neuroendocrine tumors (NET) [ 1 , 8 , 12 , 20 ]. This report describes an overview and the treatment outcomes in a case of canine PHNET with multiple metastases where long-term survival was achieved with TOC therapy.…”

mentioning

confidence: 99%

“…In 2019, Morgan et al treated a dog with a primary hepatic neuroendocrine carcinoma with metronomic chemotherapy with cyclophosphamide combined with doxorubicin, resulting in the suppression of tumor progression for 10 months and survival for 15.5 months [ 13 ]. The efficacy of TOC has also been demonstrated in dogs with insulinoma, a functional primary pancreatic NET [ 1 , 6 ]. Although the biological behavior of PHNETs in dogs is unclear, in this case, the mass shrank by up to 20% after TOC administration, and the patient survived for 25.1 months, suggesting that the PHNET might have responded to TOC and resulting in long-term survival.…”

mentioning

confidence: 99%

Long-term survival in a dog with primary hepatic neuroendocrine tumor treated with toceranib phosphate

Ichimata

Nishiyama²,

Matsuyama

et al. 2021

The Journal of Veterinary Medical Science

View full text Add to dashboard Cite

Primary hepatic neuroendocrine tumors (PHNETs) are rare in dogs, and limited information exists about the treatment of these tumors. A 12-year-old castrated male French bulldog was presented to our clinic with gastrointestinal signs. Diagnostic tests revealed increased hepatic enzyme levels, a mass in the hepatic quadrate lobe, multiple intrahepatic nodules, and enlarged hepatic hilar lymph nodes. The liver mass was diagnosed cytologically as a malignant epithelial tumor suspected to be of neuroendocrine origin. The dog was treated with single-agent toceranib phosphate (TOC) and survived 25.1 months after the initial presentation. On necropsy, a liver mass was found and was subsequently diagnosed as a PHNET on histopathology. To the best of our knowledge, this is the first report of long-term survival in a dog with PHNET treated with TOC.

show abstract

Canine and Feline Insulinoma

Buishand¹,

Kirpensteijn²

2023

Small Animal Soft Tissue Surgery

View full text Add to dashboard Cite

Evaluation of palliative therapy, alone or in combination with toceranib phosphate, in dogs diagnosed with metastatic or recurrent beta-cell neoplasia

Cited by 8 publications

References 21 publications

The role of toceranib phosphate in dogs with non‐mast cell neoplasia: A systematic review

The role of toceranib phosphate in dogs with non‐mast cell neoplasia: A systematic review

Long-term survival in a dog with primary hepatic neuroendocrine tumor treated with toceranib phosphate

Canine and Feline Insulinoma

Contact Info

Product

Resources

About